DMedical (ASX:4DX) has signed a contract with GlaxoSmithKline to supply quantitative lung imaging analytics. The agreement focuses on using 4DMedical’s technology in GSK’s drug development programs.
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.
Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed complete responses in preclinical combination studies of Pol Theta Helicase DC with ...
GSK (NYSE:GSK) is beginning to show a more assertive shift in strategy as CEO Luke Miels pushes the company toward higher-risk oncology development, with plans to launch five simultaneous late-stage ...
GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program. The recombinant protein vaccine, dubbed GSK3943104, did not meet the study’s primary efficacy ...
GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to accelerate drug development and halt the nation’s slide down global life science ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results